Searched for
ZYDUS LIFESCIENCES Q4
The AI play no one is talking about: Why BofA is snapping up power & metals instead of ITBofA Securities India's Amish Shah advises shifting from IT to infrastructure, citing a 'dangerous gap' in consensus earnings forecasts. He...- Regulator, cos discuss price hike for some cancer drugsIndia's drug pricing authority may soon approve a price hike for vital platinum-based cancer medicines. These drugs, including carboplatin ...
- Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concernsThe Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approva...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- IndiGo Q4 Results: Co reports loss of Rs 2,536 crore vs profit a year agoIndiGo Q4 Results: Budget carrier IndiGo faced a tough fourth quarter in FY26, reporting a net loss of Rs 2,536 crore. Revenue saw a slight...
- Asian Paints Q4 Results: Net profit surges 69% YoY to Rs 1,172 crore, revenue rises 11%Asian Paints announced strong Q4 FY26 results. Net profit surged 69% to Rs 1,172 crore. Revenue from operations grew 11% to Rs 9,228.46 cro...
- Supriya Lifescience shares surge 17% on strong Q4 earnings; PAT rises 47% YoYSupriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surgin...
- Stocks in news: RIL, Coal India, IDFC First Bank, Zydus Life, ONGCMarkets traded subdued with the India VIX correcting nearly 15% this week, though this hasn't significantly impacted benchmark index moveme...
- Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...
- Zydus Lifesciences hikes share buyback price to Rs 1,260 per share, lowers share countZydus Lifesciences increased its share buyback price to Rs 1,260 per share while reducing the repurchase size to 87.3 lakh shares. The tota...
- Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premiumInvestors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date i...
- Stock Radar: Zydus Lifesciences stock breaks out from inverse head & shoulder pattern to hit fresh 52-week high; time to buy?Zydus Lifesciences Ltd. broke out from an inverse head & shoulder pattern, hitting fresh 52-week highs and suggesting continued momentum. E...
- Sakar Healthcare partners with Zydus Lifesciences for GCC MarketsSakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks ...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Gainers & Losers: BEL,Zee among 6topstockmovers on WednesdayDomestic markets closed marginally higher, led by auto and bank stocks. Deccan Gold Mines surged 11% on a mineral discovery, and GE Vernova...
- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other detailsZydus Lifesciences is launching its largest share buyback program to date. The company plans to repurchase shares worth Rs 1,100 crore. Thi...
- Stocks in news: Lenskart, Apollo Hospitals, ZEE, BPCL, HindalcoIndian markets navigated a sideways trend, with analysts urging caution until the 24,000 mark is reclaimed. Key stocks like Lenskart, Apoll...
- BSE set for Nifty50 hot seat, likely to replace Wipro in September rejigAxis Capital expects BSE to replace Wipro in the NSE’s semi-annual index rebalancing, with changes likely announced in August and effective...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
Load More
